{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:29:35Z","timestamp":1792441775175,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.yebeh.2022.108711","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T11:05:07Z","timestamp":1652699107000},"page":"108711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis"],"prefix":"10.1016","volume":"132","author":[{"given":"Antonio","family":"Gil-Nagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Falip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"S\u00e1nchez-Carpintero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Reyes","family":"Abad-Sazatornil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Poveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Aibar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cardenal-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Miguel","family":"Aras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantxa","family":"Sancho-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Trillo-Mata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Torrej\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2022.108711_b0005","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1212\/WNL.0b013e3181b9c880","article-title":"Child Neurology: Dravet syndrome: when to suspect the diagnosis","volume":"73","author":"Millichap","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108711_b0010","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1111\/epi.12927","article-title":"The incidence of SCN1A-related Dravet syndrome in Denmark is 1:22,000: A population-based study from 2004 to 2009","volume":"56","author":"Bayat","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108711_b0015","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ccr3.787","article-title":"Dravet syndrome: a new causative SCN1A mutation?","volume":"5","author":"Poryo","year":"2017","journal-title":"Clin Case Reports"},{"key":"10.1016\/j.yebeh.2022.108711_b0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.yebeh.2014.12.028","article-title":"The European patient with Dravet syndrome: Results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome","volume":"44","author":"Aras","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108711_b0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2017.01.025","article-title":"Optimizing the diagnosis and management of Dravet Syndrome: RECOMMENDATIONS FROM a North American Consensus Panel","volume":"68","author":"Wirrell","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108711_b0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.yebeh.2016.09.007","article-title":"Mortality in Dravet syndrome: A review","volume":"64","author":"Shmuely","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108711_b0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1528-1167.2011.03001.x","article-title":"Dravet syndrome: the long-term outcome","volume":"52","author":"Genton","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108711_b0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eplepsyres.2016.10.006","article-title":"Mortality in Dravet syndrome","volume":"128","author":"Cooper","year":"2016","journal-title":"Epilepsy Res"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108711_b0045","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1528-1167.2011.03053.x","article-title":"Retrospective multiinstitutional study of the prevalence of early death in Dravet syndrome","volume":"52","author":"Sakauchi","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108711_b0050","first-page":"75","article-title":"Ascertaining the epidemiology, patient flow and disease management for Dravet syndrome in Spain","volume":"68","author":"Gil-Nagel","year":"2019","journal-title":"Rev Neurol"},{"key":"10.1016\/j.yebeh.2022.108711_b0055","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Datos demogr\u00e1ficos. 2021."},{"key":"10.1016\/j.yebeh.2022.108711_b0060","unstructured":"CIMA. Summary of product characteristics. Noiafren (clobazam) 2019. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/54862\/FT_54862.html."},{"key":"10.1016\/j.yebeh.2022.108711_b0065","unstructured":"CIMA. Summary of Product Characteristics (valproate EFG) 2019. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/85097\/FT_85097.html."},{"key":"10.1016\/j.yebeh.2022.108711_b9000","unstructured":"CIMA. Summary of product characteristics. Topamax (topiramate) 2019. https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/63957\/FT_63957.html."},{"key":"10.1016\/j.yebeh.2022.108711_b0070","unstructured":"(EMA) European Medicines Agency. Summary of product characteristics. Epidyolex (cannabidiol) 2020."},{"key":"10.1016\/j.yebeh.2022.108711_b0075","unstructured":"Agency EM. Epidyolex (cannabidiol) European Public Assessment Report 2019. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/epidyolex-h-c-4675-p46-002-epar-assessment-report_en.pdf."},{"key":"10.1016\/j.yebeh.2022.108711_b0080","unstructured":"Agencia Espa\u00f1ola de Medicamentos (AEMPS). CIMA - Centro de informaci\u00f3n de medicamentos 2021. https:\/\/cima.aemps.es\/cima\/publico\/home.html (accessed November 16, 2021)."},{"key":"10.1016\/j.yebeh.2022.108711_b0085","unstructured":"European Medicines Agency (EMA). Fintepla (fenfluramine) Summary of product characteristics 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fintepla-epar-product-information_en.pdf (accessed November 19, 2021)."},{"key":"10.1016\/j.yebeh.2022.108711_b0090","unstructured":"European Medicines Agency (EMA). Fintepla (fenfluramine) European Public Assessment Report. 2021."},{"issue":"1","key":"10.1016\/j.yebeh.2022.108711_b0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/epi4.12569","article-title":"Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe","volume":"7","author":"Cardenal\u2010Mu\u00f1oz","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2022.108711_b0100","unstructured":"Sociedad Espa\u00f1ola de Neurolog\u00eda (SEN). Manual de Pr\u00e1ctica Cl\u00ednica en Epilepsia. Recomendaciones diagn\u00f3stico-terap\u00e9uticas de la SEN 2019. 2019."},{"key":"10.1016\/j.yebeh.2022.108711_b0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1469-8749.2011.03967.x","article-title":"Current therapeutic procedures in Dravet syndrome","volume":"53","author":"Chiron","year":"2011","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108711_b0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40263-018-0511-y","article-title":"Treatment strategies for Dravet syndrome","volume":"32","author":"Knupp","year":"2018","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108711_b0115","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/dmcn.13591","article-title":"Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey-Spanish data set","volume":"60","author":"Lagae","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108711_b0120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.seizure.2018.12.018","article-title":"Caregiver impact and health service use in high and low severity Dravet syndrome: A multinational cohort study","volume":"65","author":"Lagae","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108711_b0125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.yebeh.2018.01.003","article-title":"Assessing the impact of caring for a child with Dravet syndrome: Results of a caregiver survey","volume":"80","author":"Campbell","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108711_b0130","doi-asserted-by":"crossref","unstructured":"Aledo-Serrano A, Mingorance A. Analysis of the family impact and needs of Dravet\u2019s syndrome in Spain. Rev Neurol 2020;70:75\u201383. 10.33588\/rn.7003.2019310.","DOI":"10.33588\/rn.7003.2019310"},{"issue":"10216","key":"10.1016\/j.yebeh.2022.108711_b0135","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108711_b0140","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: A randomized clinical trial","volume":"77","author":"Nabbout","year":"2020","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.yebeh.2022.108711_b0145","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/epi.16722","article-title":"Fenfluramine HCl (Fintepla\u00ae) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension study","volume":"61","author":"Sullivan","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108711_b0150","first-page":"1","article-title":"Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany","author":"Strzelczyk","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108711_b0155","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/epi.16690","article-title":"Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study","volume":"61","author":"Specchio","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108711_b0160","unstructured":"Committe for Orphan Medicinal Products. Public summary of opinion on orphan designation 2014:1\u20135. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-maintenance-report\/fintepla-orphan-maintenance-assessment-report_en.pdf."},{"key":"10.1016\/j.yebeh.2022.108711_b0165","unstructured":"European Comission. Fintepla Marketing Authorisation 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fintepla (accessed November 19, 2021)."},{"key":"10.1016\/j.yebeh.2022.108711_b0170","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/1472-6963-11-329","article-title":"Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada","volume":"11","author":"Tony","year":"2011","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.yebeh.2022.108711_b0175","doi-asserted-by":"crossref","unstructured":"Wahlster P, Goetghebeur M, Kriza C, Niederl\u00e4nder C, Kolominsky-Rabas P, EMN\u2019 on behalf of the NL-ECMT \u2018Medical V. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA). BMC Health Serv Res 2015;15:262. 10.1186\/s12913-015-0930-0.","DOI":"10.1186\/s12913-015-0930-0"},{"key":"10.1016\/j.yebeh.2022.108711_b0180","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1017\/S0266462317000149","article-title":"Drug evaluation and decision making in Catalonia: development and validation of a methodological framework based on Multi-Criteria Decision Analysis (MCDA) for Orphan Drugs","volume":"33","author":"Gilabert-Perramon","year":"2017","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.yebeh.2022.108711_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jval.2015.12.003","article-title":"Multiple criteria decision analysis for health care decision making - an introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force","volume":"19","author":"Thokala","year":"2016","journal-title":"Value Heal"},{"key":"10.1016\/j.yebeh.2022.108711_b0190","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jval.2015.12.016","article-title":"Multiple criteria decision analysis for health care decision making - emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force","volume":"19","author":"Marsh","year":"2016","journal-title":"Value Heal"},{"key":"10.1016\/j.yebeh.2022.108711_b0195","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/21678707.2019.1652163","article-title":"Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain","volume":"7","author":"Badia","year":"2019","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.yebeh.2022.108711_b0200","unstructured":"MedlinePlus. MedlinePlus - Informaci\u00f3n de Salud de la Biblioteca Nacional de Medicina n.d. n.d. https:\/\/medlineplus.gov\/spanish\/ (accessed January 15, 2020)."},{"key":"10.1016\/j.yebeh.2022.108711_b0205","unstructured":"Cochrane. Nuestra evidencia. Cochrane Database Syst Rev n.d. https:\/\/www.cochrane.org\/es\/evidence (accessed January 15, 2020)."},{"key":"10.1016\/j.yebeh.2022.108711_b0210","unstructured":"MEDES. El buscador de informaci\u00f3n m\u00e9dica en espa\u00f1ol. n.d. www.medes.com (accessed January 15, 2020)."},{"key":"10.1016\/j.yebeh.2022.108711_b0215","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.yebeh.2022.108711_b0220","unstructured":"European Medicines Agency (EMA). Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders 2018:1\u201330. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-clinical-investigation-medicinal-products-treatment-epileptic-disorders-revision-3_en.pdf."},{"key":"10.1016\/j.yebeh.2022.108711_b0225","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108711_b0230","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2022.108711_b0235","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/epi.14628","article-title":"Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial","volume":"60","author":"Devinsky","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108711_b0240","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1017\/S0317167100004996","article-title":"Clobazam as add-on therapy in children with epileptic encephalopathy","volume":"33","author":"Silva","year":"2006","journal-title":"Can J Neurol Sci Le J Can Des Sci Neurol"},{"key":"10.1016\/j.yebeh.2022.108711_b0245","doi-asserted-by":"crossref","first-page":"64","DOI":"10.33588\/rn.3701.2003184","article-title":"Severe myoclonic epilepsy in infancy (Dravet\u2019s syndrome). Its nosological characteristics and therapeutic aspects","volume":"37","author":"Nieto Barrera","year":"2003","journal-title":"Rev Neurol"},{"key":"10.1016\/j.yebeh.2022.108711_b0250","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0920-1211(02)00010-4","article-title":"Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial","volume":"49","author":"Coppola","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108711_b0255","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/epi4.12281","article-title":"Autism spectrum disorder and cognitive profile in children with Dravet syndrome: Delineation of a specific phenotype","volume":"4","author":"Ouss","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2022.108711_b0260","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1212\/CON.0000000000000707","article-title":"Epilepsy overview and revised classification of seizures and epilepsies","volume":"25","author":"Pack","year":"2019","journal-title":"Contin Lifelong Learn Neurol"},{"key":"10.1016\/j.yebeh.2022.108711_b8000","doi-asserted-by":"crossref","unstructured":"(EMA) European Medicines Agency. Summary of product characteristics. Diacomit (estiripentol) 2014. https:\/\/doi.org\/10.1158\/0008-5472.SABCS12-S5-3.","DOI":"10.1158\/0008-5472.SABCS12-S5-3"},{"key":"10.1016\/j.yebeh.2022.108711_b0265","unstructured":"Cross JH, Galer BS, Gil-Nagel A, al. E. Impact of fintepla (Fenfluramine) on the expected incidence rate of SUDEP in patients with Dravet syndrome. Am Epilepsy Soc Annu Meet December 4-8, 2020 2020."},{"key":"10.1016\/j.yebeh.2022.108711_b0270","unstructured":"Spanish Medicines Agency. Informe de Posicionamiento Terap\u00e9utico de cannabidiol (Epidyolex \u00ae) en el tratamiento coadyuvante del S\u00edndrome de Lennox-Gastaut y S\u00edndrome de Dravet 2021:1\u20139."},{"key":"10.1016\/j.yebeh.2022.108711_b0275","series-title":"Poster presented in ILAE Br. Branch Virtual Annu. Sci. Meet.","article-title":"Indirect treatment comparison (ITC) of fenfluramine and cannabidiol for the treatment of seizures in Dravet syndrome (DS)","author":"Linley","year":"2021"},{"key":"10.1016\/j.yebeh.2022.108711_b0280","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jval.2013.10.002","article-title":"A pilot study of multicriteria decision analysis for valuing orphan medicines","volume":"16","author":"Sussex","year":"2013","journal-title":"Value Heal"},{"key":"10.1016\/j.yebeh.2022.108711_b0285","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","article-title":"A practical guide to the treatment of Dravet syndrome with anti-seizure medication","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2022.108711_b0290","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13023-020-01507-4","article-title":"Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019","volume":"15","author":"Badia","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.yebeh.2022.108711_b0295","unstructured":"Newton M, Scott K, Troein P. EFPIA Patients W.A.I.T. Indicator 2020 Survey. WAIT (Waiting to Access Innov Ther Surv Indic 2020 2021:51. https:\/\/www.efpia.eu\/media\/602652\/efpia-patient-wait-indicator-final-250521.pdf (accessed March 23, 2022)."},{"key":"10.1016\/j.yebeh.2022.108711_b0300","doi-asserted-by":"crossref","first-page":"A570","DOI":"10.1016\/j.jval.2017.08.971","article-title":"Determining the value of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain by multi-criteria decision analysis (MCDA)","volume":"20","author":"Jimenez","year":"2017","journal-title":"Value Heal"},{"key":"10.1016\/j.yebeh.2022.108711_b0305","doi-asserted-by":"crossref","unstructured":"Alvarez Roman MT, Cuervo-Arango I, P\u00e9rez-Santamarina R, Poveda J, Romero J, Santamaria A, et al. Determining the value contribution of emicizumab (Hemlibra\u00ae) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis. Glob Reg Heal Technol Assess Ital North Eur Spanish 2019;2019:228424031988053. 10.1177\/2284240319880534.","DOI":"10.1177\/2284240319880534"},{"key":"10.1016\/j.yebeh.2022.108711_b0310","first-page":"58","article-title":"Determination of the value contribution of belantamab mafodotin (Belamaf; BLENREP\u00ae) for the treatment of triple-class refractory multiple myeloma in Spain through reflective multi-criteria decision analysis","volume":"16","author":"Casanova","year":"2021","journal-title":"Rev Espa\u00f1ola Econ La Salud"},{"key":"10.1016\/j.yebeh.2022.108711_b0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3258-9","article-title":"Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA","volume":"17","author":"Wagner","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.yebeh.2022.108711_b0320","first-page":"852","article-title":"Determinaci\u00f3n de la aportaci\u00f3n de valor de la inmunoterapia aplicada a la oncolog\u00eda en Espa\u00f1a mediante an\u00e1lisis de decisi\u00f3n multicriterio","volume":"15","author":"Abad","year":"2018","journal-title":"Econ La Salud"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022001603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022001603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:46:43Z","timestamp":1761504403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022001603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":66,"alternative-id":["S1525505022001603"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108711","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108711"}}